Almost Half Of COPD Diagnoses Are Wrong
Peter Suciu for redOrbit.com – Your Universe Online A new study has found that chronic obstructive pulmonary disease (COPD) is over-diagnosed among uninsured patients. Researchers found that over 40 percent of patients being treated for...
Latest Pulmonology Stories
The mission of the Lung Nodule Center is to provide the best chance for curing lung cancer by early diagnosis and expeditious, state-of-the-art lung cancer care. Sleepy Hollow, New York (PRWEB) May 22, 2013 Phelps Memorial Hospital Center in Sleepy Hollow, New York, has established the Westchester Lung Nodule Center for individuals who would like to be screened for lung nodules or receive lung cancer care. Lung cancer is the deadliest form of cancer for both men and women. Each year,...
Research into genetic features of pulmonary fibrosis by physicians and scientists at the University of Colorado School of Medicine may lead to improved treatment of this deadly lung disease, according to a paper published online by JAMA. The study found that a particular genetic variation helps predict survival in some cases of pulmonary fibrosis, a chronic progressive disease with a median survival of three years. As a result of the study, researchers may want to consider including...
A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease. Researchers looked at a fairly common variant of the gene for mucin-5B, a protein that is a component of the mucous produced by the bronchial tubes. While this variant of the MUC5B gene is...
OXFORD, England, May 22, 2013 /PRNewswire/ -- First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on...
NATICK, Mass., May 21, 2013 /PRNewswire/ -- Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair(® )Bronchial Thermoplasty (BT) System continues to show therapy benefits in adult patients with severe uncontrolled asthma. Bronchial Thermoplasty was shown to provide long term asthma control, demonstrated by a sustained reduction in the rate of severe exacerbations (asthma...
Boehringer Ingelheim also presents new data from a Phase 2 study demonstrating increased bronchodilation with 5 mcg tiotropium as an add-on therapy in symptomatic patients with moderate persistent asthma at the American Thoracic Society International Conference (ATS 2013) RIDGEFIELD, Conn., May 21, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of...
Non-Invasive Drug for TB Proves Effective in Easing Painful Effusion, Symptom of Late Stage Mesothelioma DALLAS (PRWEB) May 20, 2013 Chinese researchers have inadvertently stumbled on an effective, non-invasive treatment for easing pleural effusion, a distressing syndrome typical in advanced mesothelioma and other respiratory cancers. Formerly a standardized treatment for tuberculosis, the combination of four anti-bacterial drugs alleviated coughing and breathing difficulty in a...
BURLINGTON, Mass., May 20, 2013 /PRNewswire/ -- Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that the Thoraxklinik at the University of Heidelberg, Germany has taken the first OCTIS images in clinical patients with the Tomophase OCT Imaging System (OCTIS(TM)) (Photo: http://photos.prnewswire.com/prnh/20130520/PH16298-a) (Photo: http://photos.prnewswire.com/prnh/20130520/PH16298LOGO-b) On...
--Demonstration of ASM-024 adjunctive benefit with current treatments in pre-clinical asthma models-- QUEBEC CITY, May 20, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of four studies of ASM-024, Asmacure's lead compound in development for asthma and chronic obstructive pulmonary disease...
MADISON, Wis., May 20, 2013 /PRNewswire/ -- Asthmapolis (az-MAP-o-lis), the FDA-cleared mobile health solution for asthma and COPD, today announced CEO David Van Sickle will give an invited presentation during Respiratory Drug Delivery (RDD(®)) Europe 2013 in Berlin, Germany. On Friday, May 24 at 8:30 a.m., Van Sickle will present "Monitoring and Improving Compliance and Asthma Control: Mapping Inhaler Use for Feedback to Patients, Physicians and Payers" as part of the session track,...
Latest Pulmonology Reference Libraries
Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...
